PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer
Open Access
- 16 September 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 15, 5439-5455
Abstract
Background: Research has revealed that Plexin domain containing 1 (PLXDC1) is correlated with the prognosis of a variety of tumors, but its role in the tumor microenvironment (TME) of gastric cancer has not been reported. Methods: In this study, we analyzed PLXDC1 expression in gastric cancer using the Oncomine and the Cancer Genome Atlas (TCGA) databases and immunohistochemical staining experiments, and performed prognostic assessment with data from the TCGA and Kaplan–Meier Plotter databases. The immunomodulatory role of PLXDC1 in the gastric cancer TME was analyzed by signaling pathway enrichment, immune cell correlation analysis, immunomodulator risk model construction and immunohistochemical staining experiments of immune cells. Results: The results indicated that PLXDC1 was overexpressed in gastric cancer and that its overexpression was associated with poor prognosis. Multivariate Cox analysis revealed that PLXDC1 could be an independent biomarker of the risk of gastric cancer. Signaling pathway enrichment revealed that high PLXDC1 expression was involved in signaling pathways related to immune activation and stromal activation, and Tumor Immune Dysfunction and Exclusion (TIDE) assessment indicated that high PLXDC1 expression was associated with a significantly higher risk of immune evasion than low PLXDC1 expression. A Cox risk model based on PLXDC1-associated immunomodulators also presented poor prognosis, and immune evasion was significantly higher in the high-risk group than in the low-risk group. In addition, immunohistochemical staining of CD8/CD3/CD4+ T cells in the high and low PLXDC1 expression groups also observed immune cell distribution characteristics of immune evasion. Conclusion: This study analyzed PLXDC1 from multiple biological perspectives and revealed that PLXDC1 can be a biomarker for poor prognosis and immune evasion in gastric cancer. Graphical Abstract:Keywords
This publication has 59 references indexed in Scilit:
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast CancerNew England Journal of Medicine, 2012
- The parallel lives of angiogenesis and immunosuppression: cancer and other talesNature Reviews Immunology, 2011
- Gene set enrichment analysis: performance evaluation and usage guidelinesBriefings in Bioinformatics, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Gene Expression Signature–Based Prognostic Risk Score in Gastric CancerClinical Cancer Research, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- The Hallmarks of CancerCell, 2000
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971